Intranasal Dihydroergotamine Mesylate for Acute Migraine Treatment
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
STOP 301: A Phase 3, Open-Label Study of Safety, Tolerability, and Exploratory Efficacy of INP104, Precision Olfactory Delivery (POD® ) of Dihydroergotamine Mesylate, Over 24/52 Weeks in Acute Treatment of Migraine Attacks in Adult Patients
Headache 2021 Aug 07;[EPub Ahead of Print], TR Smith, P Winner, SK Aurora, M Jeleva, J Hocevar-Trnka, SB ShrewsburyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.